IBDEI1TM ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32084,2)
 ;;=^5009025
 ;;^UTILITY(U,$J,358.3,32085,0)
 ;;=L03.032^^182^1981^104
 ;;^UTILITY(U,$J,358.3,32085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32085,1,3,0)
 ;;=3^Cellulitis of Left Toe
 ;;^UTILITY(U,$J,358.3,32085,1,4,0)
 ;;=4^L03.032
 ;;^UTILITY(U,$J,358.3,32085,2)
 ;;=^5009026
 ;;^UTILITY(U,$J,358.3,32086,0)
 ;;=L03.041^^182^1981^26
 ;;^UTILITY(U,$J,358.3,32086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32086,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,32086,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,32086,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,32087,0)
 ;;=L03.042^^182^1981^20
 ;;^UTILITY(U,$J,358.3,32087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32087,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,32087,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,32087,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,32088,0)
 ;;=M34.0^^182^1981^250
 ;;^UTILITY(U,$J,358.3,32088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32088,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,32088,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,32088,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,32089,0)
 ;;=M34.1^^182^1981^91
 ;;^UTILITY(U,$J,358.3,32089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32089,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,32089,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,32089,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,32090,0)
 ;;=M34.2^^182^1981^274
 ;;^UTILITY(U,$J,358.3,32090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32090,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,32090,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,32090,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,32091,0)
 ;;=M34.81^^182^1981^276
 ;;^UTILITY(U,$J,358.3,32091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32091,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,32091,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,32091,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,32092,0)
 ;;=M34.82^^182^1981^277
 ;;^UTILITY(U,$J,358.3,32092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32092,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,32092,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,32092,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,32093,0)
 ;;=M34.83^^182^1981^278
 ;;^UTILITY(U,$J,358.3,32093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32093,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,32093,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,32093,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,32094,0)
 ;;=M34.89^^182^1981^275
 ;;^UTILITY(U,$J,358.3,32094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32094,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,32094,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,32094,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,32095,0)
 ;;=M34.9^^182^1981^279
 ;;^UTILITY(U,$J,358.3,32095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32095,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,32095,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,32095,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,32096,0)
 ;;=R21.^^182^1981^258
 ;;^UTILITY(U,$J,358.3,32096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32096,1,3,0)
 ;;=3^Rash/Nonspecific Skin Eruption
 ;;^UTILITY(U,$J,358.3,32096,1,4,0)
 ;;=4^R21.
 ;;^UTILITY(U,$J,358.3,32096,2)
 ;;=^5019283
 ;;^UTILITY(U,$J,358.3,32097,0)
 ;;=R23.3^^182^1981^270
 ;;^UTILITY(U,$J,358.3,32097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32097,1,3,0)
 ;;=3^Spontaneous Ecchymoses
 ;;^UTILITY(U,$J,358.3,32097,1,4,0)
 ;;=4^R23.3
 ;;^UTILITY(U,$J,358.3,32097,2)
 ;;=^5019295
 ;;
 ;;$END ROU IBDEI1TM
